Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-08-28
2011-11-29
McGarry, Sean (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S024100, C514S04400A
Reexamination Certificate
active
08067575
ABSTRACT:
This invention relates to compounds, compositions, and methods useful for modulating cyclin (e.g., cyclin D1) and/or cyclin dependent kinase (CDK) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of cyclin (e.g., cyclin D1) and/or cyclin dependent kinase (CDK) gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of cyclin (e.g., cyclin D1) and/or cyclin dependent kinase (CDK) genes.
REFERENCES:
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 5998206 (1999-12-01), Cowsert
patent: 6107094 (2000-08-01), Crooke
patent: 6258601 (2001-07-01), Monia et al.
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0157514 (2003-08-01), Finger et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2006/0178326 (2006-08-01), Robbins et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 2359180 (2000-03-01), None
patent: WO-90/14090 (1990-11-01), None
patent: WO-94/01550 (1994-01-01), None
patent: WO-99/32619 (1999-07-01), None
patent: WO-99/49029 (1999-09-01), None
patent: WO-00/44895 (2000-08-01), None
patent: WO-00/44914 (2000-08-01), None
patent: WO-01/36646 (2001-05-01), None
patent: WO-01/96584 (2001-12-01), None
patent: WO-01/96584 (2001-12-01), None
patent: WO-02/22636 (2002-03-01), None
patent: WO-02/44321 (2002-06-01), None
patent: WO-02/44321 (2002-06-01), None
patent: WO-03/064626 (2003-08-01), None
patent: WO-03/064626 (2003-08-01), None
Pieken, et al. (1991) Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes. Science, v.253:314-7.
Office Action mailed on Mar. 17, 2008 for U.S. Appl. No. 10/893,010, 11 pages.
Anderson et al. “Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance,”Oligonucleotides13(5):303-312 (2003).
Elbashir et al. “Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs,”Methods26(2):199-213 (2002).
Elbashir et al. “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,”Nature411(6836):494-498 (2001).
Elbashir et al. “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate,”EMBO J. 20(23):6877-6888 (2001).
Elbashir et al. “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,”Genes Dev. 15(2):188-200 (2001).
Fire et al. “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans,” Nature391:806-811 (1998).
Futami et al. “Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against Bcl-2,”Nucleic Acids Research Supplement2:251-252 (2002).
International Search Report mailed on Mar. 31, 2005 for PCT/US04/16390, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05028, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05346, 1 page.
Leirdal et al. “Gene Silencing in Mammalian Cells by Preformed Small RNA Duplexes,”Biochemical and Biophysical Research Communications295:744-748 (2002).
Lin et al. “A Novel mRNA-cDNA Interference Phenomenon for Silencing Bcl-2 Expression in Human LNCaP Cells,”Biochemical and Biophysical Research Communications281:639-644 (2001).
Parrish et al.,Mol. Cell. Biol. 6:1077-1087 (2000).
Tuschl et al. “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,”Molecular Interventions295(3):158-167 (2002).
Tuschl et al. “Targeted mRNA Degradation by Double-Stranded RNA In Vitro,”Genes and Development13(24):3191-3197 (1999).
Office Action mailed on Feb. 4, 2008 for U.S. Appl. No. 10/444,853, 37 pages.
Office Action mailed on Jul. 1, 2008 for U.S. Appl. No. 11/499,520, 13 pages.
Office Action mailed on Oct. 8, 2008 for U.S. Appl. No. 11/499,529, 34 pages.
Office Action mailed on Nov. 14, 2008 for U.S. Appl. No. 11/502,875, 14 pages.
Office Action mailed on Apr. 8, 2009 for U.S. Appl. No. 11/502,876, 31 pages.
Office Action mailed on Jan. 26, 2009 for U.S. Appl. No. 11/676,124, 15 pages.
Office Action mailed on Feb. 3, 2009 for U.S. Appl. No. 10/693,059, 7 pages.
Office Action mailed on Jul. 2, 2008 for U.S. Appl. No. 10/757,803, 26 pages.
Office Action mailed on Apr. 16, 2009 for U.S. Appl. No. 12/105,010, 24 pages.
Office Action mailed on Jul. 10, 2007 for U.S. Appl. No. 10/893,010, 10 pages.
Beigelman Leonid
McSwiggen James
McGarry Sean
Merck Sharp & Dohme Corp.
LandOfFree
RNA interference mediated inhibition of cyclin D1 gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNA interference mediated inhibition of cyclin D1 gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA interference mediated inhibition of cyclin D1 gene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4270970